Trial Profile
A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalized Anxiety Disorder
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2015
Price :
$35
*
At a glance
- Drugs BNC 210 (Primary) ; Lorazepam
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Bionomics
- 20 Apr 2015 According to Bionomics media release, the results are expected in third quarter of 2016.
- 20 Apr 2015 According to Bionomics media release, status changed from planning to recruiting.
- 13 Nov 2014 New trial record